Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Cancer Research Communications|February 26, 2024
Immune Profiling of Vulvar Squamous Cell Cancer Discovers a Macrophage-rich Subtype Associated with Poor PrognosisMateja Condic, Andrea Rohr, Soheila Riemann, et al.
BMC Cancer|May 14, 2020
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsSvenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, et al.
The American Journal of Surgical Pathology|September 25, 2013
Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testingHelen Künstlinger, Sebastian Huss, Sabine Merkelbach-Bruse, et al.
Histopathology|July 2, 2013
Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinomaNils C Lehnen, Anne von Mässenhausen, Holger Kalthoff, et al.
Virchows Archiv : an International Journal of Pathology|August 9, 2024
High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methodsUdo Siebolts, Roberto Pappesch, Marcus Bauer, et al.
BMC Medical Genetics|July 6, 2010
Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumorsSabine Merkelbach-Bruse, Wolfgang Dietmaier, Laszlo Füzesi, et al.
Plos One|February 17, 2018
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatmentMichaela Angelika Ihle, Sebastian Huss, Wiebke Jeske, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostatMichaela Angelika Ihle, Sabine Merkelbach-Bruse, Wolfgang Hartmann, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2018
Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesRoberta Castiglione, Christina Alidousty, Barbara Holz, et al.
BMC Gastroenterology|February 6, 2019
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinomaAlexander Quaas, Carina Heydt, Dirk Waldschmidt, et al.
Pageof 17